These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20684988)

  • 1. MPN-associated myelofibrosis (MPN-MF).
    Mesa RA; Green A; Barosi G; Verstovsek S; Vardiman J; Gale RP
    Leuk Res; 2011 Jan; 35(1):12-3. PubMed ID: 20684988
    [No Abstract]   [Full Text] [Related]  

  • 2. Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?
    Barosi G; Magrini U; Gale RP
    Leuk Res; 2010 Sep; 34(9):1119-20. PubMed ID: 20538336
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth?
    Barosi G; Gale RP
    Leuk Res; 2011 May; 35(5):563-5. PubMed ID: 21296418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
    Tefferi A; Hudgens S; Mesa R; Gale RP; Verstovsek S; Passamonti F; Cervantes F; Rivera C; Tencer T; Khan ZM
    Clin Ther; 2014 Apr; 36(4):560-6. PubMed ID: 24636526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group.
    Simpson-Poirier K; Harnois M; Olney HJ; Sirhan S; Gratton MO; Assouline S; Laneuville P; Delage R; Mollica L; Busque L; Szuber N
    Am J Hematol; 2021 Jun; 96(6):E200-E203. PubMed ID: 33719144
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
    Benton CB; Tanaka M; Wilson C; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2015 Apr; 39(4):419-23. PubMed ID: 25687833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary hypertension with massive megalosplenia: A case report.
    Yi T; Ma W; Qiu J; Ding W
    Medicine (Baltimore); 2019 Mar; 98(12):e14594. PubMed ID: 30896614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombotic incidents in patients with myelofibrosis suggest to be independent of
    Nikolova D; Radinov A
    Folia Med (Plovdiv); 2022 Aug; 64(4):655-660. PubMed ID: 36045460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.
    Barosi G; Klersy C; Villani L; Bonetti E; Catarsi P; Poletto V; Campanelli R; Impera S; Latagliata R; Viarengo G; Carolei A; Massa M; Musso M; Crescimanno A; Gale RP; Rosti V
    Leukemia; 2016 Aug; 30(8):1772-5. PubMed ID: 26975727
    [No Abstract]   [Full Text] [Related]  

  • 11. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.
    Marchetti M; Carobbio A; Capitoni E; Barbui T
    Am J Hematol; 2018 May; 93(5):698-703. PubMed ID: 29377227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible myelofibrosis?
    Lancet; 1985 Mar; 1(8427):497-9. PubMed ID: 2857858
    [No Abstract]   [Full Text] [Related]  

  • 13. Chorea with transitional myeloproliferative disease.
    Coppack SW; Gibberd FB
    J R Soc Med; 1985 Oct; 78(10):864-6. PubMed ID: 4045892
    [No Abstract]   [Full Text] [Related]  

  • 14. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical management of the haemorrhagic complications of myeloproliferative neoplasms.
    Jones E; Dillon B; Swan D; Thachil J
    Br J Haematol; 2022 Nov; 199(3):313-321. PubMed ID: 35724983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate deficiency in the myeloproliferative disorders.
    Chanarin I
    Am J Clin Nutr; 1970 Jun; 23(6):855-60. PubMed ID: 5431049
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of polycythemia vera in a patient with myeloid metaplasia and myelofibrosis. Report of a case with a comment on its significance in relation to prevailing views on myeloid metaplasia.
    Hershko C; Polliack A
    Isr J Med Sci; 1971 Feb; 7(2):315-20. PubMed ID: 5560987
    [No Abstract]   [Full Text] [Related]  

  • 18. Pleural extramedullary haematopoiesis in myelosclerosis.
    Anton HC; Ferguson JB; Lewis GP
    Postgrad Med J; 1967 Jun; 43(500):428-32. PubMed ID: 6043695
    [No Abstract]   [Full Text] [Related]  

  • 19. [Metamorphosis of chronic myeloproliferative diseases].
    Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.